Joseph Tauber, MD.

KANSAS CITY, Mo.—Vital Tears, a leader in the development and delivery of autologous serum tears, has announced the appointment of Joseph Tauber, MD, as its chief medical officer (CMO). This strategic addition to the leadership team reflects Vital Tears' commitment to continuous innovation in the field of ocular surface health, according to the company. Dr. Tauber is a respected ophthalmologist in practice here. He is a graduate of Harvard Medical School with dual fellowship training in the treatment and surgery of corneal diseases and ocular immunology.

Dr. Tauber is also an internationally recognized authority on ocular surface disease and dry eye treatment and a regional specialist in the treatment of complex ocular infections. He has been a principal investigator in more than 150 research studies of high-risk corneal transplantation, inflammation and allergic eye diseases, corneal infectious diseases and numerous studies related to dry eye syndrome.

In his new role, Dr. Tauber will lead Vital Tears’ research and development initiatives, provide physician education and training; act as the primary medical liaison between Vital Tears and the medical community; and support Vital Tears’ market access initiatives to expand insurance coverage of serum tears.

 
“We are thrilled to welcome Dr. Tauber to our executive team as chief medical officer. His extensive background in cornea and ocular surface disease and commitment to patient care align perfectly with Vital Tears’ mission to enhance our patients’ quality of life through the delivery of life-changing treatments,” said Rajan Shukla, president of Vital Tears.